ChiCTR2100052294 版本V1.3 版本创建时间2022/04/26 18:22:23 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100052294 

最近更新日期:

Date of Last Refreshed on:

2022-04-26 18:20:29 

注册时间:

Date of Registration:

2021-10-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

低阿片多模式镇痛方案对老年患者术后恢复质量的影响:一项单中心、前瞻、随机、对照研究

Public title:

Effect of low opioid multimodal analgesia on postoperative recovery quality in elderly patients: a single center, prospective, randomized, controlled study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

低阿片多模式镇痛方案对老年患者术后恢复质量的影响:一项单中心、前瞻、随机、对照研究

Scientific title:

Effect of low opioid multimodal analgesia on postoperative recovery quality in elderly patients: a single center, prospective, randomized, controlled study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杜娟 

研究负责人:

杜娟 

Applicant:

Du Juan 

Study leader:

Du Juan 

申请注册联系人电话:

Applicant telephone:

+86 13583522560

研究负责人电话:

Study leader's telephone:

+86 13583522560

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

641181767@qq.com

研究负责人电子邮件:

Study leader's E-mail:

641181767@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省烟台市芝罘区毓璜顶东路20号

研究负责人通讯地址:

山东省烟台市芝罘区毓璜顶东路20号

Applicant address:

20 Yuhuangding Road East, Zhifu District, Yantai, Shandong

Study leader's address:

20 Yuhuangding Road East, Zhifu District, Yantai, Shandong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

烟台毓璜顶医院

Applicant's institution:

Yantai Yuhuangding Hospital

研究负责人所在单位:

烟台毓璜顶医院

Affiliation of the Leader:

Yantai Yuhuangding Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

烟毓医伦理审(2021-321)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

烟台毓璜顶医院医学伦理委员会

Name of the ethic committee:

Yantai Yuhuangding Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2021-09-15 00:00:00

伦理委员会联系人:

高振利

Contact Name of the ethic committee:

Gao Zhenli

伦理委员会联系地址:

山东省烟台市芝罘区毓璜顶东路20号

Contact Address of the ethic committee:

20 Yuhuangding Road East, Zhifu District, Yantai, Shandong

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

烟台毓璜顶医院

Primary sponsor:

Yantai Yuhuangding Hospital

研究实施负责(组长)单位地址:

山东省烟台市芝罘区毓璜顶东路20号

Primary sponsor's address:

20 Yuhuangding Road East, Zhifu District, Yantai, Shandong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

烟台

Country:

China

Province:

Shandong

City:

Yantai

单位(医院):

烟台毓璜顶医院

具体地址:

芝罘区毓璜顶东路20号

Institution
hospital:

Yantai Yuhuangding Hospital

Address:

20 Yuhuangding Road East, Zhifu District

经费或物资来源:

山东省医学会临床科研专项资金

Source(s) of funding:

Special fund for clinical scientific research of Shandong Medical Association

Target disease:

N/A

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

本课题拟探索针对老年患者的低阿片围术期多模式镇痛方案,促进术后康复。  

Objectives of Study:

This topic intends to explore a low-opioid perioperative multimodal analgesia program for elderly patients to promote postoperative recovery.

药物成份或治疗方案详述:

研究组患者入室后静脉注射帕瑞昔布钠40mg。全麻诱导前静脉泵注负荷剂量右美托咪定0.7μg/kg(持续泵注约10min),并恒速静脉输注右美托咪定0.5μg/kg/h至术毕前30min,对照组泵注等量生理盐水。研究组中腹腔镜手术切皮前以0.5%罗哌卡因行切口局部浸润麻醉,开腹手术在B超引导下行双侧腹横肌平面神经阻滞(每侧0.375%罗哌卡因20ml),对照组不实施此操作。术中镇痛以输注瑞芬太尼维持。两组术后镇痛均采用负荷剂量+患者自控静脉(PCIA),手术结束前15 min对照组和研究组分别给予舒芬太尼5μg或布托啡诺0.5mg和帕洛诺司琼0.25 mg,患者自控镇痛泵药物配制:研究组右美托咪定0.1μg/kg/h(最大剂量300μg)+布托啡诺0.125 mg/kg(最大剂量10mg);对照组舒芬太尼1.25μg/kg(最大剂量100μg)。持续+注药设定总量100 ml,速率为2 ml/h,自控镇痛量为0.5ml,锁定时间为15 min。 

Description for medicine or protocol of treatment in detail:

The patients in the experimental group received an intravenous injection of parecoxib sodium 40 mg after admission. Before induction of general anesthesia, a loading dose of dexmedetomidine 0.7 μg/kg was injected intravenously (continuous infusion for about 10 minutes), and dexmedetomidine 0.5 μg/kg/h was intravenously infused at a constant rate until 30 minutes before the end of the operation. The control group was injected with the same volume of normal saline. In the experimental group, local infiltration anesthesia was performed with 0.5% ropivacaine before laparoscopic skin incision, and bilateral transversus abdominis plane nerve block (0.375% ropivacaine 20ml on each side) was performed under the guidance of B-ultrasound for laparotomy, the control group did not implement this operation. Intraoperative analgesia was maintained with remifentanil infusion. Postoperative analgesia in both groups were given loading dose + patient-controlled intravenous (PCIA), and the control group and the experimental group were given 5 μg sufentanil or 0.5 mg butorphanol and 0.25 mg palonosetron, respectively, 15 minutes before the end of the operation, patient-controlled analgesia pump preparation: experimental group dexmedetomidine 0.1 μg/kg/h (maximum dose 300 μg) + butorphanol 0.125 mg/kg (maximum dose 10 mg); the control group received sufentanil 1.25 μg/kg (maximum dose 100 μg). The total volume of continuous + injection is 100 ml, the rate is 2 ml/h, the volume of patient-controlled analgesia is 0.5 ml, and the locking time is 15 minutes. 

纳入标准:

1. ASA Ⅱ或III级;
2. 65岁-85岁,男女不限;
3. 手术时间长于1.5 h,择期腹腔镜或开腹上腹部手术(胃、胆囊、肝脏、胰腺、脾脏)的患者;
4.意识清楚且主动配合,经短暂培训可以理解疼痛视觉模拟评分(VAS)评分、镇静评分等,能自主使用PCA装置。

Inclusion criteria

1. ASA II or III;
2. Aged 65-85 years, no gender limit;
3. Patients with elective laparoscopic or open upper abdominal surgery (stomach, gallbladder, liver, pancreas, spleen) whose operation time is longer than 1.5 hours;
4. Clear consciousness and active cooperation, can understand pain visual analog scale (VAS) score, sedation score, etc. after short training, and can use PCA device autonomously.

排除标准:

1.心功能严重异常;
2.慢性呼吸功能不全;
3.肝肾功能严重异常(谷丙转氨酶高于正常3倍或肌酐高于正常);
4.患有中枢神经系统和心理疾病、慢性疼痛病史,术前长期服用镇静药、抗抑郁药,酗酒、药物依赖等,有中枢呼吸抑制危险。

Exclusion criteria:

1. Severely abnormal cardiac function;
2. Chronic respiratory insufficiency;
3. Serious abnormality of liver and kidney function (alanine aminotransferase is 3 times higher than normal or creatinine is higher than normal);
4. Suffering from central nervous system and psychological diseases, history of chronic pain, long-term use of sedatives, antidepressants, alcoholism, drug dependence, etc. before surgery, there is a risk of central respiratory depression.

研究实施时间:

Study execute time:

From 2021-11-01 00:00:00 To 2023-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-11-01 00:00:00 To 2023-09-30 00:00:00  

干预措施:

Interventions:

组别:

对照组

样本量:

60

Group:

Control group

Sample size:

干预措施:

对照组镇痛方案

干预措施代码:

Intervention:

Control group analgesia

Intervention code:

组别:

试验组

样本量:

60

Group:

Experimental group

Sample size:

干预措施:

试验组镇痛方案

干预措施代码:

Intervention:

Analgesia in the experimental group

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

烟台 

Country:

China 

Province:

Shandong 

City:

Yantai 

单位(医院):

烟台毓璜顶医院 

单位级别:

三级甲等 

Institution
hospital:

Yantai Yuhuangding Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

平均动脉压

指标类型:

主要指标

Outcome:

mean arterial pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

主要指标

Outcome:

heart rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血氧饱和度

指标类型:

主要指标

Outcome:

blood oxygen saturation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

苏醒时间

指标类型:

主要指标

Outcome:

wake up time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视觉模拟评分法疼痛和镇静评分

指标类型:

主要指标

Outcome:

visual analogue scale pain and sedation score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后胃肠功能

指标类型:

主要指标

Outcome:

postoperative gastrointestinal function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后恢复情况

指标类型:

主要指标

Outcome:

postoperative recovery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表由统计人员提供,利用SAS软件按B1、B2组1:1的比例随机化方法产生随机编码,借助统计软件SAS过程语句,给定种子数,产生受试者所接受处理的随机编码表。筛选合适的患者,按就诊先后顺序依次分入随机编码对应的处理组别。

Randomization Procedure (please state who generates the random number sequence and by what method):

The random number table is provided by the statistician. The random code is generated by using SAS software according to the 1:1 ratio of B1 and B2 groups. With the help of SAS process statement of statistical software and given the number of seeds, the random code table processed by the subject

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

实验结束后6个月共享数据,共享方式为resman数据库

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Six months after the experiment, the data was shared in resman database

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF和EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF and EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-10-24 01:54:32